Immunotherapy has emerged as a promising cancer treatment modality. Despite the rapid
progress in cancer immunotherapy, the therapeutic efficiency and clinical translation of …

Cancer immunotherapy has produced impressive clinical results in recent years. Despite the
success of the checkpoint blockade strategies targeting cytotoxic T lymphocyte antigen 4 …

Background T cell immunoglobulin-3 (TIM-3) has been established as a negative regulatory
molecule and plays a critical role in immune tolerance. TIM-3 is upregulated in exhausted …

In the last two years, clinical trials with blocking antibodies to the negative checkpoint
regulators CTLA-4 and PD-1 have rekindled the hope for cancer immunotherapy. Multiple …

The immune system is capable of distinguishing between danger-and non-danger signals,
thus inducing either an appropriate immune response against pathogens and cancer or …

T cell inhibitory co-receptors play a crucial role in maintaining the balance between
physiologic immune responses and maladaptive ones. T cell immunoglobulin and mucin …

T‐cell immunoglobulin and mucin domain 3 (TIM‐3) is an Ig‐superfamily member expressed
on IFN‐γ‐secreting Th1 and Tc1 cells and was identified as a negative regulator of immune …

Inflammation is closely related to the extent of damage following cerebral ischaemia, and the
targeting of this inflammation has emerged as a promising therapeutic strategy. Here, we …

In recent years, an important role has emerged for the glycan‐binding protein Galectin‐9
(Gal‐9) in health and disease. In normal physiology, Gal‐9 seems to be a pivotal modulator …

Immune-checkpoint blockade therapy with antibodies targeting CTLA-4 and PD-1 has
revolutionized melanoma treatment by eliciting responses that can be remarkably durable …